Cardiff Park Advisors’s GSK GSK Stock Holding History

Cardiff Park Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,520	Closed	-$360K	–	376
2026 Q1	$360K	Buy	+6,520	New	+$353K	0.03%	213
2025 Q4	–	Sell	-7,520	Closed	-$325K	–	366
2025 Q3	$325K	Buy	+7,520	New	+$294K	0.02%	226
2024 Q2	–	Sell	-14,959	Closed	-$641K	–	346
2024 Q1	$641K	Buy	+14,959	New	+$617K	0.06%	139
2022 Q4	–	Sell	-11,008	Closed	-$324K	–	319
2022 Q3	$324K	Buy	11,008 +83	+0.8%	+$3.15K	0.05%	178
2022 Q2	$594K	Buy	10,925 +138	+1%	+$7.62K	0.09%	123
2022 Q1	$587K	Buy	10,787 +119	+1%	+$6.46K	0.08%	126
2021 Q4	$588K	Buy	+10,668	New	+$555K	0.08%	127

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cardiff Park Advisors's GSK Position: Q2 2026 in Review

Cardiff Park Advisors sold out of GSK (GSK) in Q2 2026, closing a stake of 6,520 shares — an estimated $360K sold.

Cardiff Park Advisors first reported a position in GSK in Q4 2021 and held it in 7 quarters. The position peaked at $641K in Q1 2024. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cardiff Park Advisors reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Cardiff Park Advisors sold 6,520 GSK shares in Q2 2026, an estimated $360K.
Cardiff Park Advisors first reported a position in GSK in Q4 2021 and held it in 7 quarters.
Cardiff Park Advisors's GSK position peaked at $641K in Q1 2024.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cardiff Park Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.